Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CEP1347 |
Synonyms | |
Therapy Description |
CEP1347 inhibits PAK and MLK family kinases, which potentially induces differentiation and inhibits cancer stem cell self-renewal and tumor growth (PMID: 29212273, PMID: 12184411). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CEP1347 | CEP-1347|CEP 1347 | CEP1347 inhibits PAK and MLK family kinases, which potentially induces differentiation and inhibits cancer stem cell self-renewal and tumor growth (PMID: 29212273, PMID: 12184411). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | meningioma | sensitive | CEP1347 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CEP-1347 induced apoptosis, inhibited viability, and decreased colony formation in a TP53 wild-type meningioma cell line in culture and inhibited tumor growth in a cell line xenograft model (PMID: 37509605). | 37509605 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|